Hologic Inc (HOLX) Stock Price, Quote & News

Company Profile

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, an...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 508 263 2900

Website: www.hologic.com

Address:

250 Campus Drive, Marlborough, United States

StockAutoPro Oct. 4 at 9:14 PM

$HOLX: Buy target $66.22 Sell target $71.63 Expect increased growth potential due to rising demand in women's health diagnostic products.

0 · Reply

MoneyGroupLLC Oct. 3 at 5:49 PM

Enter: $HOLX NOV 21 2025 $68 CALLS Buy in Price: $3.10 - $3.20 Take Profit: $7.16 Stop Bleeding: $2.73 ROI Potential: 131% Exit Within: 191 Minutes https://moneygroup.us/alerts

0 · Reply

ZacksResearch Oct. 3 at 12:30 PM

$HOLX gets a boost with FDA clearance for new GI assays! 🚀 The Panther Fusion GI assays, now FDA-cleared and CE-marked, are expected to support growth in Hologic's Diagnostics division, which is a key revenue component, thanks to their rapid, sensitive detection of bacterial pathogens. This development may bolster investor confidence and maintain an upward momentum in HOLX's share price in the coming days. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2761306/holx-stock-gains-on-fda-ce-approval-for-automated-molecular-gi-tests?cid=sm-stocktwits-2-2761306-body-14577&ADID=SYND_STOCKTWITS_TWEET_2_2761306_BODY_14577

0 · Reply

ZacksResearch Oct. 3 at 11:30 AM

$HOLX pops on dual approvals 🚀 Shares are gaining after FDA clearance and CE mark for its rapid molecular GI assays on the Panther Fusion platform. See what this means for growth potential here 👉 https://www.zacks.com/stock/news/2761306/holx-stock-gains-on-fda-ce-approval-for-automated-molecular-gi-tests?cid=sm-stocktwits-2-2761306-teaser-14576&ADID=SYND_STOCKTWITS_TWEET_2_2761306_TEASER_14576

0 · Reply

prismmarketview Oct. 2 at 7:25 PM

Hologic (NASDAQ: $HOLX) secures FDA clearance and CE Mark for its Panther Fusion assays to rapidly detect bacterial causes of infectious gastroenteritis. The new tests expand its Panther platform, supporting faster, more accurate patient care. https://prismmarketview.com/hologic-receives-fda-clearance-and-ce-mark-for-automated-molecular-tests-to-detect-infectious-gastroenteritis/

0 · Reply

StockAutoPro Oct. 2 at 6:21 PM

$HOLX: Buy target $65.22 Sell target $70.59 Potential growth observed in medical technology company due to increased demand for women's health products.

0 · Reply

MahiMe Oct. 2 at 12:06 PM

$HOLX https://www.stocktitan.net/news/HOLX/hologic-receives-fda-clearance-and-ce-mark-for-automated-molecular-eqnt34w4plhf.html

0 · Reply

SuperGreenToday Oct. 1 at 8:35 PM

$HOLX Share Price: $67.02 Contract Selected: Mar 20, 2026 $70 Calls Buy Zone: $3.06 – $3.78 Target Zone: $5.48 – $6.70 Potential Upside: 69% ROI Time to Expiration: 169 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

ZacksSCR Oct. 1 at 3:38 PM

$VNRX: Two (2) licensing agreements signed during September, specifically for Nu.Q NETs research related to APS in humans with Werfen S.A. and for Nu.Q Discover services with $HOLX https://buff.ly/VEkieEo

0 · Reply

stingrae Oct. 1 at 1:38 PM

$HOLX tick tock

0 · Reply

Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2025 on Monday, November 3, 2025

Oct 2, 2025, 8:05 AM EDT - 2 days ago

Hologic Receives FDA Clearance and CE Mark for Automated Molecular Tests to Detect Common Causes of Infectious Gastroenteritis

Sep 30, 2025, 8:15 AM EDT - 4 days ago

New Survey Results Underscore the Need to #BustTheMyth About Mammograms

Sep 29, 2025, 9:30 AM EDT - 5 days ago

Volition Signs Co-Marketing and Services Agreement with Hologic

VNRX

Sep 29, 2025, 9:30 AM EDT - 5 days ago

Minicarm.com Named Exclusive U.S. Distributor of Hologic's Fluoroscan® Insight FD Mini C-Arm

Sep 26, 2025, 8:00 AM EDT - 8 days ago

New Data on Hologic's AI-Powered Mammography Technology to Be Presented at EUSOBI

Sep 17, 2025, 4:41 PM EDT - 17 days ago

Blackstone and TPG revive interest in buying Hologic, source says

BX TPG

Sep 9, 2025, 2:05 PM EDT - 25 days ago

Hologic, Inc. (HOLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 3, 2025, 4:02 PM EDT - 4 weeks ago

Hologic to Webcast Presentation at the 23rd Annual Morgan Stanley Global Healthcare Conference

Jul 30, 2025, 7:12 PM EDT - 2 months ago

Hologic, Inc. (HOLX) Q3 2025 Earnings Call Transcript

Jul 30, 2025, 6:06 PM EDT - 2 months ago

Hologic raises annual profit forecast on diagnostic and surgical demand

Jul 30, 2025, 4:01 PM EDT - 2 months ago

Hologic Announces Financial Results for Third Quarter of Fiscal 2025

Jul 22, 2025, 5:06 PM EDT - 2 months ago

Hologic Q3 Preview: Tariff Pressure And Undervalued Stock Price, Initiate With Buy

Jul 2, 2025, 4:05 PM EDT - 3 months ago

Hologic to Announce Financial Results for the Third Quarter of Fiscal 2025 on Wednesday, July 30, 2025

Jun 2, 2025, 11:03 AM EDT - 4 months ago

Hologic Joins NEST Governance Committee to Advance the Use of Real-World Data in Medical Device Evaluation

May 27, 2025, 3:48 PM EDT - 4 months ago

Why Is Diagnostic Firm Hologic Stock Trading Higher On Tuesday?

May 27, 2025, 1:05 PM EDT - 4 months ago

Hologic rejects $16 billion take-private proposal from TPG and Blackstone, Financial Times reports

BX TPG

May 22, 2025, 5:05 PM EDT - 4 months ago

Hologic to Present New Data at ASCO 2025 Reinforcing the Practice-Changing Role of the Breast Cancer Index® Test in Helping to Deliver More Personalized Care to Patients

May 13, 2025, 4:10 PM EDT - 5 months ago

Hologic to Webcast Presentations at Upcoming Investor Conferences

May 6, 2025, 5:39 PM EDT - 5 months ago

Hologic: Soft Performance, But Cheap Enough

May 1, 2025, 8:24 PM EDT - 5 months ago

Hologic, Inc. (HOLX) Q2 2025 Earnings Call Transcript

May 1, 2025, 6:58 PM EDT - 5 months ago

Medical equipment maker Hologic lowers annual profit forecast on tariff uncertainty

May 1, 2025, 4:01 PM EDT - 5 months ago

Hologic Announces Financial Results for Second Quarter of Fiscal 2025

Apr 25, 2025, 4:25 AM EDT - 5 months ago

Cellulite Treatment Market Trends, Growth Opportunities and Shares 2025-2030; Featuring Key Players - Hologic (Cynosure), Merz Pharma, Syneron Medical, Zimmer Aesthetics & More

Apr 24, 2025, 8:10 AM EDT - 5 months ago

Groundbreaking New Data on Hologic's AI-Powered Mammography Technology to Be Presented at SBI

Apr 22, 2025, 8:08 AM EDT - 5 months ago

Hologic Details Environmental, Social and Governance Efforts — Including Expanded Environmental Ambitions — in New Sustainability Report

Apr 4, 2025, 4:15 PM EDT - 6 months ago

Wayde McMillan Elected to Hologic Board of Directors

Apr 3, 2025, 4:30 PM EDT - 6 months ago

Hologic to Announce Financial Results for the Second Quarter of Fiscal 2025 on Thursday, May 1, 2025

Feb 25, 2025, 8:15 AM EST - 7 months ago

Hologic to Webcast Presentation at the Raymond James 46th Annual Institutional Investors Conference

Feb 20, 2025, 3:00 AM EST - 8 months ago

Hologic Obtains CE Mark for Affirm® Contrast Biopsy Software

Feb 18, 2025, 8:08 AM EST - 8 months ago

Hologic Announces FDA Clearance of Aptima SARS-CoV-2 Assay

Feb 5, 2025, 10:06 PM EST - 8 months ago

Hologic, Inc. (HOLX) Q1 2025 Earnings Call Transcript

Feb 5, 2025, 5:56 PM EST - 8 months ago

Hologic cuts annual revenue forecast on weak demand for breast health products

Feb 5, 2025, 4:01 PM EST - 8 months ago

Hologic Announces Financial Results for First Quarter of Fiscal 2025

Jan 21, 2025, 8:00 AM EST - 9 months ago

New Report Reveals Alarming Decline in Women's Cancer Testing Worldwide

Jan 17, 2025, 1:28 PM EST - 9 months ago

Hologic: Reasonably, But Not Compellingly Valued

Jan 12, 2025, 4:00 PM EST - 9 months ago

Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2025

Jan 7, 2025, 4:04 PM EST - 9 months ago

Hologic to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 4:15 PM EST - 9 months ago

Hologic to Announce Financial Results for the First Quarter of Fiscal 2025 on Wednesday, February 5, 2025

Jan 6, 2025, 8:05 AM EST - 9 months ago

Hologic Completes Acquisition of Gynesonics, Inc.

Jan 3, 2025, 12:06 PM EST - 9 months ago

Healthcare has 'been so bad, maybe it's gonna be good' in 2025, says Mizuho's Jared Holz

ABT BMY LLY NVO UNH XBI XLV

Dec 18, 2024, 8:08 AM EST - 10 months ago

Hologic to Contribute to H5N1 Bird Flu Test Development via Agreement Issued by CDC

Dec 10, 2024, 4:01 PM EST - 10 months ago

Hologic Statement on USPSTF Draft Cervical Cancer Screening Guidelines

Dec 9, 2024, 4:05 PM EST - 10 months ago

Martin Madaus Elected to Hologic Board of Directors

Dec 9, 2024, 8:05 AM EST - 10 months ago

New Data To Be Presented at SABCS 2024 Investigates the Potential Role of the Breast Cancer Index® Test in Identifying Patients With Minimal Risk of Distant Recurrence

Dec 2, 2024, 8:08 AM EST - 10 months ago

Hologic Presents New Research Demonstrating How Its Breast Imaging AI Solution Performs Similarly Across Diverse Populations

Nov 25, 2024, 8:22 AM EST - 11 months ago

Hologic Invites Attendees to Step Into the Future of Breast Health and AI at RSNA 2024

Nov 4, 2024, 7:26 PM EST - 11 months ago

Hologic, Inc. (HOLX) Q4 2024 Earnings Call Transcript

Nov 4, 2024, 4:01 PM EST - 11 months ago

Hologic Announces Financial Results for Fourth Quarter of Fiscal 2024

Oct 19, 2024, 2:00 PM EDT - 1 year ago

Hologic to acquire Gynesonics in $350M deal to boost Fibroid treatments

StockAutoPro Oct. 4 at 9:14 PM

$HOLX: Buy target $66.22 Sell target $71.63 Expect increased growth potential due to rising demand in women's health diagnostic products.

0 · Reply

MoneyGroupLLC Oct. 3 at 5:49 PM

Enter: $HOLX NOV 21 2025 $68 CALLS Buy in Price: $3.10 - $3.20 Take Profit: $7.16 Stop Bleeding: $2.73 ROI Potential: 131% Exit Within: 191 Minutes https://moneygroup.us/alerts

0 · Reply

ZacksResearch Oct. 3 at 12:30 PM

0 · Reply

ZacksResearch Oct. 3 at 11:30 AM

0 · Reply

prismmarketview Oct. 2 at 7:25 PM

0 · Reply

StockAutoPro Oct. 2 at 6:21 PM

$HOLX: Buy target $65.22 Sell target $70.59 Potential growth observed in medical technology company due to increased demand for women's health products.

0 · Reply

MahiMe Oct. 2 at 12:06 PM

$HOLX https://www.stocktitan.net/news/HOLX/hologic-receives-fda-clearance-and-ce-mark-for-automated-molecular-eqnt34w4plhf.html

0 · Reply

SuperGreenToday Oct. 1 at 8:35 PM

0 · Reply

ZacksSCR Oct. 1 at 3:38 PM

0 · Reply

stingrae Oct. 1 at 1:38 PM

$HOLX tick tock

0 · Reply

stingrae Sep. 30 at 7:20 PM

$HOLX Wants to go here but sellers saying not so fast.

0 · Reply

highnihilism Sep. 30 at 10:23 AM

$HOLX Hologic: 79 trades, $54K vs $196K avg (0.27x !!). $33K calls / $21K puts. $MIST Milestone Pharma: 47 trades, $33K vs $22K avg (1.52x). $33K calls / $0.1K puts. $EYPT Eyepoint Pharma: 43 trades, $37K vs $28K avg (1.31x). $33K calls / $5K puts. $TTI Tetra Tech: 87 trades, $35K vs $35K avg (0.99x). $33K calls / $2K puts.

1 · Reply

highnihilism Sep. 29 at 6:28 PM

S&P MidCap 400 (Health Care) → $CYH Community Health Systems $DRRX Durect Corporation $HCA HCA Healthcare $HOLX Hologic $IART Integra LifeSciences

0 · Reply

NetworkNewsWire Sep. 29 at 3:55 PM

NetworkNewsBreaks – $VNRX Signs Co-Marketing and Services Agreement with $HOLX https://nnw.fm/8kn4H

0 · Reply

MoneyGroupLLC Sep. 29 at 5:58 AM

Enter: $HOLX NOV 21 2025 $70 CALLS Buy in Price: $2.40 - $2.43 Take Profit: $4.98 Stop Bleeding: $2.14 ROI Potential: 105% Exit Within: 98 Minutes https://moneygroup.us/alerts

0 · Reply

SweepCastApp Sep. 28 at 6:48 PM

$HOLX: Unusual Options Activity Alerted CALL flow observed 1000x contracts at Strike price of $70 Exp on 10/17/2025 with Premium of $119K and showing BULLISH Sentiment

0 · Reply

victorgn Sep. 27 at 11:45 PM

Breakout candidates $SEE $HOLX $NXPI $ADBE

0 · Reply

SweepCastApp Sep. 26 at 9:28 AM

$HOLX: TRADE CALL orders came through 500 @ 2.05, Strike 67.5, Exp 10/17/2025, Premium $102,500, Sentiment BULLISH

0 · Reply

MoneyGroupLLC Sep. 25 at 7:11 PM

Enter: $HOLX OCT 17 2025 $68 CALLS Buy in Price: $2.45 - $2.99 Take Profit: $4.99 Stop Bleeding: $2.63 ROI Potential: 67% Exit Within: 78 Minutes https://moneygroup.us/alerts

0 · Reply

highnihilism Sep. 24 at 7:11 PM

Russell 2000 (Healthcare) → $EXAS Exact Sciences $GH Guardant Health $GKOS Glaukos $HCA HCA Healthcare $HOLX Hologic

0 · Reply

ZacksResearch Sep. 24 at 2:40 PM

$HOLX shares up 11.2% in 6 months — trading at a 15.10X forward P/E vs. industry’s 27.17X 📈 🚀 Strong Q3 performance driven by 62.1% sales jump in Skeletal Health, due to Horizon DXA production ramp-up & easing supply challenges 🔍 Zacks Rank #3 (Hold) suggests a mixed earnings outlook See what makes the investment case strong for HOLX 👉 https://www.zacks.com/stock/news/2756311/holx-to-discontinue-fluoroscan-insight-fd-soon-will-the-stock-suffer?cid=sm-stocktwits-2-2756311-body-13923&ADID=SYND_STOCKTWITS_TWEET_2_2756311_BODY_13923

0 · Reply

ZacksResearch Sep. 24 at 1:36 PM

$HOLX phasing out Fluoroscan InSight FD — red flag for the stock? The company announced it will discontinue the product soon, raising questions about how investors should view the impact. Full breakdown here 👉 https://www.zacks.com/stock/news/2756311/holx-to-discontinue-fluoroscan-insight-fd-soon-will-the-stock-suffer?cid=sm-stocktwits-2-2756311-teaser-13892&ADID=SYND_STOCKTWITS_TWEET_2_2756311_TEASER_13892

0 · Reply

Market Cap	15.10B
Revenue (ttm)	4.03B
Net Income (ttm)	789.50M
EPS (ttm)	N/A
PE Ratio	16.15
Forward PE	14.95
Profit Margin	19.59%
Debt to Equity Ratio	0.52

Volume	1,158,300
Avg Vol	1,948,254
Day's Range	N/A - N/A
Shares Out	222.42M
Stochastic %K	77%
Beta	0.63
Analysts	Sell
Price Target	$75.00